-
Feb 16, 2024 Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
-
Nov 21, 2023 Apotex Corp. Launches Teriparatide Injectable for Osteoporosis Treatment in the United States
-
Sep 5, 2023 Apotex Corp. Launches Brimonidine Tartrate Ophthalmic Solution, 0.1% in the United States
-
Apr 26, 2023 Apotex Corp. Launches Bendamustine Hydrochloride Injection in the United States
-
Apr 19, 2023 Apotex Receives FDA’s Drug Shortage Assistance Award
-
Mar 1, 2023 Apotex Corp. Issues Voluntary Nationwide Recall of Brimonidine Tartrate Ophthalmic Solution, 0.15% due to cracks that have developed in some of the units caps of the bottles
-
Apr 12, 2022 Apotex Corp. Launches Generic of Abraxane® in the United States
-
Jan 19, 2022 Apotex Corp. Launches First-to-Market Authorized Generic Version of Combigan® Ophthalmic Solution in the United States
-
Dec 7, 2021 Apotex Corp. Announces Approval and Launch of Atropine Sulfate Ophthalmic Solution USP, 1% in the United States
-
Oct 7, 2021 Product Donation Supports Clinical Study to Evaluate FDA-Approved Medications for Mild-to-Moderate COVID-19 in Outpatients
-
Mar 31, 2021 Apotex Corp. Issues Voluntary Nationwide Recall of Guanfacine Extended-Release Tablets 2mg due to trace amounts of Quetiapine Fumarate
-
Dec 2, 2020 Apotex Corp. names new President & Chief Executive Officer
-
Jun 5, 2020 Apotex Corp. Issues Voluntary Nationwide Recall of Metformin Hydrochloride Extended-Release Tablets 500mg Due to the Detection of N-nitrosodimethylamine (NDMA)
-
May 27, 2020 Apotex Corp. Issues Voluntary Nationwide Recall of Metformin Hydrochloride Extended-Release Tablets 500mg Due to the Detection of N-nitrosodimethylamine (NDMA)
-
May 7, 2020 Apotex Corp. Resolves US Federal Government Antitrust Investigation Regarding Generic Drug Pricing
-
Sep 25, 2019 Apotex Corp. Issues Voluntary Nationwide Recall of Ranitidine Tablets 75mg and 150mg (All pack sizes and Formats) due to the potential for Detection of an Amount of Unexpected Impurity,N-nitrosodimethylamine (NDMA) Impurity in the product
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Aug 12, 2026
Apotex Announces First Quarter 2027 Results
TORONTO, ON, August 12, 2026 – Apotex Health Corp. ("Apotex" or the "Company") (TSX: APTX), a Canadian-based global health company and Canada's largest pharmaceutical company, today announced its financial and operating results for the three months ended June 30, 2026. All financial figures are in Canadian dollars unless otherwise indicated.
-
Jul 17, 2026
Apotex Receives Investment Grade Issuer Rating from Morningstar DBRS and Announces Amended & Restated Credit Agreement
Toronto, ON, July 16, 2026. Apotex Health Corp ("Apotex" or the "Company") (TSX: APTX) today announced the successful completion of an amended and restated credit agreement ("Amended Credit Agreement"), establishing a financing framework aligned with the Company's evolution as a publicly traded, investment-grade-rated issuer.
-
Jul 8, 2026
Apotex expands U.S. hospital portfolio with launch of generic Infuvite® Adult and Pediatric Injection
Toronto, ON, July 8, 2026 – Apotex Health Corp. ("Apotex") (TSX: APTX) today announced the U.S. launch of four product configurations of its generic equivalents of Infuvite® Pediatric Injection and Infuvite® Adult Injection. Of the four configurations launched, the Adult Bulk and Pediatric Single presentations received Competitive Generic Therapy (CGT) exclusivity.